51.1 Peripheral Arterial Disease & Claudication

Epidemiology, Pathophysiology & Systemic Burden of PAD

Peripheral Arterial Disease (PAD) is defined as atherosclerotic stenosis or occlusion of the arterial vasculature supplying the extremities, predominantly the lower limbs. Affecting over 200 million individuals worldwide and approximately 8.5 million adults in the United States, PAD prevalence rises sharply with age, exceeding 15% to 20% in individuals older than 70 years.

PAD as a Coronary Heart Disease Risk Equivalent

A fundamental clinical principle for family physicians and internists is that PAD is not merely a localized limb problem; it is a manifestation of diffuse, systemic atherosclerotic disease:

• Cardiovascular Overlap: More than 50% to 60% of patients diagnosed with lower extremity PAD have concurrent, clinically significant coronary artery disease (CAD), and up to 30% have concomitant cerebrovascular disease.
• Cardiovascular Mortality: PAD is designated a Coronary Heart Disease (CHD) risk equivalent. Patients diagnosed with PAD carry a 15% to 30% all-cause mortality rate at 5 years.
• Cause of Death: Crucially, 70% to 80% of deaths in patients with PAD are attributable to systemic cardiovascular events (acute myocardial infarction, sudden cardiac death, and ischemic stroke). In contrast, fewer than 2% to 4% of patients with intermittent claudication will ever require a major lower limb amputation over a 5-year period. Therefore, medical management must prioritize aggressive secondary cardiovascular prevention alongside limb-directed therapy.

Clinical Classifications of Lower Limb Ischemia

Two primary clinical staging classifications are utilized in vascular medicine: the Fontaine Classification and the Rutherford Classification.

                    CLINICAL CLASSIFICATION SYSTEMS FOR PAD

   Fontaine Stage   Rutherford Category   Clinical Presentation / Description
   ═════════════════════════════════════════════════════════════════════════════════════════════
   Stage I          Category 0            Asymptomatic (documented flow-limiting disease, no pain)
   Stage IIa        Category 1            Mild intermittent claudication (> 200 meters walking)
   Stage IIb        Category 2 - 3        Moderate-to-severe claudication (< 200 meters walking)
   Stage III        Category 4            Ischemic rest pain (forefoot/toes; worse supine)
   Stage IV         Category 5            Minor tissue loss (non-healing ischemic ulcer / focal gangrene)
   Stage IV         Category 6            Major tissue loss (extensive gangrene extending past metatarsals)
   ═════════════════════════════════════════════════════════════════════════════════════════════

---

Clinical Manifestations: Intermittent Claudication vs. CLTI

Lower extremity ischemia spans a wide clinical spectrum, ranging from completely asymptomatic disease to life- and limb-threatening tissue gangrene.

1. Intermittent Claudication

Intermittent claudication is the classic clinical manifestation of mild-to-moderate arterial insufficiency:

• Pathophysiology: Fixed proximal atherosclerotic stenosis creates a fixed resistance to arterial inflow. At rest, baseline collateral blood flow suffices to meet the low metabolic requirements of resting skeletal muscle. During ambulation, the metabolic demand of contracting leg muscles surges by 10- to 20-fold. Flow across the fixed stenosis cannot increase adequately, precipitating severe tissue hypoxia. Anaerobic metabolism produces lactate, potassium, bradykinin, and adenosine, which stimulate sensory chemoreceptors in muscle beds, producing pain.
• Clinical Presentation: Patients describe a deep, aching, cramping, heaviness, or muscle fatigue localized to specific lower extremity muscle groups:
  • Calf Claudication: The most frequent presentation (>70% of symptomatic cases), reflecting flow-limiting disease in the superficial femoral artery or popliteal artery.
  • Thigh and Buttock Claudication: Indicates proximal obstruction within the common iliac artery, external iliac artery, or distal aorta.
  • Foot / Arch Claudication: Infrequent, reflecting isolated tibial, peroneal, or pedal arch occlusions (characteristic of thromboangiitis obliterans [Buerger disease] or severe diabetic microangiopathy).
• The Cardinal Features of Vascular Claudication:
  1. The pain is strictly exertional and reproducible at a predictable walking distance or workload (e.g., walking 1.5 blocks on level ground, or earlier when walking uphill or briskly).
  2. The discomfort never begins at rest.
  3. The pain is completely relieved within 5 to 10 minutes of standing still or resting in place (the patient does not need to sit down or flex their spine; simply stopping muscular contraction halts ischemia and restores tissue oxygen balance).

                  VASCULAR CLAUDICATION VS. NEUROGENIC CLAUDICATION

   Clinical Feature           Vascular Claudication                Neurogenic Claudication (Spinal Stenosis)
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════
   Underlying Etiology        Arterial atherosclerotic stenosis    Lumbar spinal canal stenosis (cauda equina)
   Pain Character             Aching, cramping, fatigue, heaviness Paresthetic, burning, tingling, numbness
   Location of Pain           Muscle group (calf, thigh, buttock)  Dermatomal, bilateral buttocks, posterolateral leg
   Provoking Factor           Predictable walking distance         Prolonged walking OR prolonged standing
   Effect of Standing Still   Rapid relief (< 5 to 10 minutes)     NO relief; standing sustains neural compression
   Postural Dependence       None; relieved standing upright     Relieved by lumbar spine flexion ("shopping cart")
   Peripheral Pulses          Diminished or absent                 Normal and bounding
   Skin & Nails               Pale, cool, trophic changes, rubor   Normal skin temperature and nail morphology
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════

2. Leriche Syndrome (Aortoiliac Occlusive Disease)

Severe, chronic atherosclerotic occlusion of the distal abdominal aorta and bilateral common iliac arteries produces the classic Leriche Syndrome triad:

1. Bilateral buttock, hip, and thigh claudication (with or without calf claudication);
2. Absent or severely diminished bilateral femoral pulses; and
3. Erectile dysfunction in men (due to inadequate arterial inflow via the internal iliac and internal pudendal arteries into the corpora cavernosa).

3. Chronic Limb-Threatening Ischemia (CLTI / Critical Limb Ischemia)

Chronic Limb-Threatening Ischemia represents the most advanced stage of peripheral atherosclerosis, where arterial perfusion is insufficient to meet the baseline metabolic requirements of resting tissues. It is defined by the presence of documented peripheral arterial disease combined with ischemic rest pain, non-healing ischemic ulcers, or gangrene present for >=2 weeks.

• Ischemic Rest Pain:
  • A severe, gnawing, burning, or aching pain localized to the forefoot and toes.
  • Supine Worsening: Rest pain characteristically worsens at night when the patient is lying flat in bed. In the supine position, the beneficial hydrostatic effect of gravity on distal arterial perfusion pressure is lost, causing perfusion pressure in the pedal microcirculation to plunge below the critical threshold required for capillary patency.
  • Dependent Relief: Patients learn to relieve the agonizing pain by dangling the affected foot over the side of the bed or sleeping upright in a recliner chair, recruiting gravitational hydrostatic pressure to augment distal capillary flow. Consequently, dependent edema in a limb with severe arterial ischemia is common and reflects this compensatory posturing.
• Ischemic Ulcerations:
  • Characteristically located at distal, trauma-prone pressure points: the tips of the toes, interdigital web spaces, metatarsal heads, and over the lateral malleolus or heel.
  • Appearance: Classic "punched-out" sharply demarcated borders, a pale, dry, or gray-yellow necrotic base with absent or minimal granulation tissue, and minimal or absent exudate/bleeding.
  • Differentiated from venous stasis ulcers, which are shallow, irregularly bordered, exudative, located over the medial malleolus ("gaiter region"), and surrounded by stasis dermatitis and hyperpigmentation.
• Gangrene:
  • Dry Gangrene: Coagulative necrosis resulting from profound ischemia in the absence of bacterial superinfection. The tissue becomes dry, shriveled, blackened, mummified, and sharply demarcated from viable tissue. If uninfected and stable, it can occasionally be managed with protective dry dressings and expectant autoamputation.
  • Wet Gangrene: Liquefactive necrosis occurring when dry gangrene becomes superinfected with pathogenic bacteria (often polymicrobial: staphylococci, streptococci, anaerobes). Characterized by soft, swollen, foul-smelling necrotic tissue, active purulence, crepitus, and rapidly ascending cellulitis. Wet gangrene is a surgical emergency requiring emergent broad-spectrum IV antibiotics and immediate surgical debridement or amputation to prevent lethal septic shock.

---

Physical Examination & Bedside Vascular Hemodynamics

Bedside evaluation of the arterial tree provides critical diagnostic information and determines the urgency of intervention.

Comprehensive Vascular Palpation & Auscultation

• Pulse Examination: Bilateral palpation of the femoral, popliteal, dorsalis pedis (DP), and posterior tibial (PT) arteries. Pulses are graded on a standard 0 to 4+ scale:
  • 0: Absent;
  • 1+: Markedly diminished / faint;
  • 2+: Normal;
  • 3+: Bounding / hyperdynamic (often seen in aortic regurgitation);
  • 4+: Aneurysmal. (Note: The dorsalis pedis pulse is congenitally absent in approximately 8% to 10% of healthy individuals; however, an absent posterior tibial pulse is virtually always pathologic and indicates arterial stenosis).
• Auscultation for Bruits: Stethoscope auscultation over the abdominal aorta, common iliac arteries, and femoral arteries. A systolic-diastolic bruit over the femoral artery confirms high-grade (>50%) flow-limiting arterial stenosis.

Trophic Cutaneous Features

Chronically ischemic microcirculation produces characteristic trophic changes:

• Thin, taut, shiny, "parchment-like" skin;
• Complete loss of hair on the lower legs, dorsum of the foot, and toes;
• Thickened, brittle, slow-growing, opaque toenails with transverse ridges;
• Cool or cold skin temperature, particularly when comparing the affected limb to the contralateral side;
• Subcutaneous tissue atrophy and muscle wasting of the calf and foot.

Elevation Pallor & Dependent Rubor (The Buerger Test)

1. Elevation Pallor: With the patient lying supine, both lower extremities are elevated to 45 to 60 degrees for 1 to 2 minutes while the examiner inspects the plantar surface of the feet. In healthy extremities, pink color is maintained. In limbs with severe arterial stenosis, the low perfusion pressure cannot overcome gravity, causing rapid, striking blanching (cadaveric elevation pallor within 30-60 seconds).
2. Dependent Rubor: The patient is then asked to sit upright with both legs hanging down over the examination table. In healthy limbs, normal pink color returns within 10 seconds. In severe PAD, blood flow returns sluggishly (venous filling time >20 to 30 seconds), followed by the gradual appearance of an intense, deep dusky reddish-purple erythema (dependent rubor).
   • Mechanism of Dependent Rubor: Chronic tissue ischemia induces maximal, refractory autoregulatory dilation of the distal cutaneous capillary and arteriolar beds. When blood finally trickles into these maximally dilated vessels under gravitational hydrostatic pressure, the capillaries become engorged with deoxygenated blood, producing a misleading flushed, red appearance that is frequently misdiagnosed as cellulitis or gout. Dependent rubor blanches poorly and rapidly disappears upon re-elevation of the limb.

---

Non-Invasive Vascular Diagnostic Testing

                  DIAGNOSTIC STRATIFICATION IN PERIPHERAL ARTERIAL DISEASE

   Diagnostic Test       Indication / Clinical Scenario        Diagnostic Threshold / Interpretation
   ═════════════════════════════════════════════════════════════════════════════════════════════════
   Resting Ankle-        First-line test for suspected PAD;    <= 0.90: Diagnostic of PAD
   Brachial Index (ABI)  exertional leg symptoms, ulcers       • 0.71 - 0.90: Mild obstruction
                                                               • 0.41 - 0.70: Moderate obstruction
                                                               • <= 0.40: Severe / critical ischemia
                                                               0.91 - 0.99: Borderline
                                                               1.00 - 1.30: Normal baseline
                                                               > 1.30 or > 1.40: Incompressible / calcified

   Toe-Brachial          Mandatory when resting ABI is         <= 0.70: Diagnostic of PAD in the
   Index (TBI)           incompressible (> 1.30 or > 1.40)     presence of calcified tibial vessels;
                         in diabetes or advanced CKD           Absolute toe pressure < 30 mmHg = poor healing

   Exercise ABI          Normal (1.00-1.30) or borderline      Post-exercise drop in ABI > 15% to 20% OR
   Testing (Treadmill)   resting ABI with classic symptoms     post-exercise ankle systolic BP drop > 20 mmHg
                         of exertional claudication            confirms flow-limiting arterial stenosis
   ═════════════════════════════════════════════════════════════════════════════════════════════════

1. Resting Ankle-Brachial Index (ABI)

The resting Ankle-Brachial Index (ABI) is the gold-standard initial non-invasive screening and diagnostic test for PAD, offering >90% sensitivity and >95% specificity.

• Measurement Technique:
  • The patient rests supine in a warm room for at least 10 minutes.
  • A handheld 5- to 10-MHz continuous-wave Doppler ultrasound probe and a calibrated sphygmomanometer cuff are used.
  • Systolic blood pressure is measured in both brachial arteries (the higher of the two brachial pressures is utilized as the universal denominator for both limbs).
  • Ankle cuffs are applied just proximal to the malleoli, and systolic pressures are measured in both the dorsalis pedis (DP) and posterior tibial (PT) arteries of each leg.
  • For each limb, the higher of the DP or PT systolic pressure serves as the numerator: $\text{Right ABI} = \frac{\text{Higher of Right DP or Right PT Systolic Pressure}}{\text{Higher of Left or Right Brachial Systolic Pressure}}$ $\text{Left ABI} = \frac{\text{Higher of Left DP or Left PT Systolic Pressure}}{\text{Higher of Left or Right Brachial Systolic Pressure}}$
• ABI Interpretation Guidelines:
  • 1.00 to 1.30 (or 1.40): Normal. Ankle pressures are normally slightly higher than brachial pressures due to pulse-wave reflection.
  • 0.91 to 0.99: Borderline. Inconclusive; warrants exercise testing if symptomatic.
  • <= 0.90: Abnormal; Diagnostic of Lower Extremity PAD:
    • 0.71 to 0.90: Mild arterial insufficiency (frequently asymptomatic or mild claudication);
    • 0.41 to 0.70: Moderate arterial insufficiency (typical claudication);
    • <= 0.40: Severe arterial insufficiency (strongly associated with ischemic rest pain, non-healing ulcers, and high risk of limb loss).

2. The Incompressible Vessel Dilemma & Toe-Brachial Index (TBI)

In patients with long-standing diabetes mellitus, chronic kidney disease (CKD), or end-stage renal disease (ESRD), extensive dystrophic medial arterial calcification (Mönckeberg medial calcific sclerosis) develops within the muscular layers of tibial and peroneal vessels.

• The Diagnostic Trap: The calcified arterial wall becomes rigid and non-compliant, resisting external compression by the blood pressure cuff. The cuff must be inflated to extreme supra-physiological pressures (often >250-300 mmHg) before the Doppler signal ceases, yielding a falsely elevated ABI of >1.30 or >1.40.
• Actionable Mandate: An ABI >1.30 or >1.40 is NON-DIAGNOSTIC and NEVER excludes PAD. When an incompressible ABI is encountered in a symptomatic patient, the clinician must immediately obtain a Toe-Brachial Index (TBI).
• Mechanism of TBI: Digital arteries supplying the toes are tiny muscular arterioles that lack an extensive internal elastic lamina and are characteristically spared from medial calcific sclerosis. A miniature pneumatic cuff is applied to the proximal phalanx of the great toe, and digital pulsation is recorded using photoplethysmography (PPG): $\text{TBI} = \frac{\text{Toe Systolic Blood Pressure}}{\text{Higher Brachial Systolic Pressure}}$
  • A TBI <= 0.70 is diagnostic of PAD.
  • An absolute toe systolic pressure < 30 mmHg indicates severe chronic limb-threatening ischemia and correlates with poor spontaneous healing of foot ulcers without revascularization.

3. Exercise Ankle-Brachial Index Testing

Exercise ABI testing is indicated in patients who present with typical history and symptoms of exertional claudication but exhibit normal (1.00-1.30) or borderline (0.91-0.99) resting ABIs:

• Protocol: Performed on a motorized treadmill at 2.0 mph (3.2 km/h) on a 10% to 12% incline for up to 5 minutes, or until claudication forces the patient to stop.
• Diagnostic Threshold: In healthy individuals, exercise induces profound muscular vasodilation, but flow increases without a fall in ankle systolic pressure. In patients with hemodynamically significant but compensated proximal arterial stenosis, maximal exercise-induced distal vasodilation causes a steep pressure drop across the stenosis. A post-exercise decrease in ankle systolic pressure >20 mmHg or a reduction in post-exercise ABI >15% to 20% confirms the diagnosis of PAD.

---

Comprehensive Medical Management of PAD

Optimal management of PAD involves a multi-pronged strategy targeting both systemic cardiovascular risk reduction and lower-limb functional preservation.

                    THE 7 PILLARS OF MEDICAL MANAGEMENT IN PAD

   Therapeutic Domain             Specific Intervention & Evidence Target
   ═════════════════════════════════════════════════════════════════════════════════════════════
   1. Antiplatelet /              Aspirin 81 mg daily OR Clopidogrel 75 mg daily;
      Antithrombotic Therapy      Dual Pathway Inhibition: Rivaroxaban 2.5 mg BID + Aspirin 100 mg daily

   2. Lipid Lowering              High-intensity statin (Atorvastatin 80 mg or Rosuvastatin 20-40 mg);
                                  Target >= 50% LDL-C reduction; aim for LDL < 55-70 mg/dL

   3. Blood Pressure Control      Target BP < 130/80 mmHg; ACE inhibitors (Ramipril 10 mg) or ARBs first-line

   4. Glycemic Control            Target HbA1c < 7.0%; SGLT2 inhibitors and GLP-1 receptor agonists

   5. Smoking Cessation           Mandatory counseling; Varenicline, Bupropion, or NRT combinations

   6. Exercise Therapy            Supervised Exercise Therapy (SET; Grade 1A recommendation);
                                  >= 30-45 min/session, >= 3x/week for >= 12 weeks; walk to moderate pain

   7. Symptom Pharmacotherapy     Cilostazol 100 mg BID (PDE-3 inhibitor; increases walking distance);
                                  STRICTLY CONTRAINDICATED in heart failure (increased mortality)
   ═════════════════════════════════════════════════════════════════════════════════════════════

1. Antithrombotic Therapy: Single vs. Dual Pathway

• Single Antiplatelet Therapy (SAPT):
  • Indicated for all patients with symptomatic PAD to reduce the risk of myocardial infarction, ischemic stroke, and vascular death.
  • Aspirin: 75 to 100 mg daily (standard 81 mg daily in the US); OR
  • Clopidogrel: 75 mg daily. In the landmark CAPRIE trial, clopidogrel monotherapy demonstrated an 8.7% relative risk reduction in ischemic events compared to aspirin monotherapy, with the greatest clinical benefit observed specifically in the subgroup of patients with PAD.
• Dual Pathway Inhibition (Rivaroxaban + Aspirin):
  • The COMPASS trial and VOYAGER PAD trial demonstrated that targeting both platelet aggregation and thrombin generation produces superior vascular outcomes.
  • Regimen: Low-dose Rivaroxaban (2.5 mg orally twice daily) PLUS Aspirin (100 mg orally daily).
  • Clinical Benefit: Significantly reduced Major Adverse Cardiovascular Events (MACE; cardiovascular death, MI, stroke) by 24% and Major Adverse Limb Events (MALE; acute limb ischemia, major vascular amputation) by 46% compared to aspirin alone, with a modest increase in major bleeding (but no significant difference in fatal or intracranial hemorrhage). Recommended for patients with symptomatic PAD at high risk of limb or cardiovascular events and low bleeding risk.

2. High-Intensity Statin Therapy

• Mandate: All patients with PAD require high-intensity statin therapy regardless of baseline cholesterol levels (e.g., Atorvastatin 80 mg daily or Rosuvastatin 20 to 40 mg daily).
• Mechanism & Endpoints: Lowers LDL-C by >=50%, stabilizes vulnerable atherosclerotic plaques across the coronary and carotid beds, reduces all-cause and cardiovascular mortality, and significantly improves pain-free walking distance and functional treadmill performance.

3. Blood Pressure Optimization

• Target: Blood pressure <130/80 mmHg.
• Preferred Classes: Angiotensin-Converting Enzyme (ACE) Inhibitors (e.g., Ramipril 10 mg daily) or Angiotensin Receptor Blockers (ARBs). In the landmark HOPE trial, ramipril significantly reduced MI, stroke, and cardiovascular death in patients with PAD, independent of baseline blood pressure reduction.
• Clinical Nuance on Beta-Blockers: Beta-blockers are safe in PAD and are NOT contraindicated in mild-to-moderate claudication. They should be prescribed whenever compelling indications exist (e.g., prior myocardial infarction, heart failure with reduced ejection fraction).

4. Smoking Cessation

• Tobacco use is the single most potent, modifiable etiologic risk factor for PAD inception and progression. Cigarette smoking increases the risk of PAD by fourfold, accelerates disease progression, increases amputation rates by tenfold, and significantly increases graft failure following bypass surgery.
• Interventions: Aggressive multimodal support combining structured behavioral counseling with pharmacotherapy: Varenicline (nicotinic receptor partial agonist; most effective single agent), Bupropion SR, and combination Nicotine Replacement Therapy (NRT) (nicotine patch plus nicotine gum/lozenge).

5. Supervised Exercise Therapy (SET)

Supervised Exercise Therapy carries a Grade 1A recommendation from the ACC/AHA and is the single most effective non-invasive treatment for increasing walking performance in claudication.

• Standard Protocol:
  • Conducted in a hospital outpatient or cardiac rehabilitation facility under direct supervision.
  • Frequency: At least 3 sessions per week.
  • Duration: 30 to 45 minutes per session.
  • Minimum Program Length: At least 12 consecutive weeks.
  • Modality: Motorized treadmill walking.
  • The Claudication Threshold Technique: The patient walks at a workload that induces moderate-to-severe claudication pain (claudication score 3-4 out of 4) within 3 to 5 minutes. The patient then stops and rests standing or sitting until the claudication pain completely subsides, whereupon walking resumes. This cycle of exercise-pain-rest-recovery is repeated throughout the 30- to 45-minute session.
• Physiological Mechanisms: SET promotes muscular angiogenesis, stimulates the development of collateral bypass vessels around occluded arterial segments, restores endothelial nitric oxide synthase activity, and enhances skeletal muscle mitochondrial density and oxidative enzyme capacity.
• Comparison: SET improves maximal walking distance by 120% to 150% and is dramatically superior to unsupervised "walk at home" advice.

6. Symptom-Directed Pharmacotherapy: Cilostazol

• Mechanism: Cilostazol (100 mg orally twice daily taken on an empty stomach, 30 minutes before or 2 hours after breakfast and dinner) is a selective phosphodiesterase-3 (PDE-3) inhibitor. It inhibits cellular cAMP degradation, resulting in elevated intracellular cAMP in platelets and vascular smooth muscle. This induces potent inhibition of platelet aggregation, suppresses vascular smooth muscle proliferation, and produces direct arterial vasodilation.
• Efficacy: Improves pain-free walking distance by 40% to 50% and improves overall quality of life.

[!CAUTION] BLACK BOX WARNING: CILOSTAZOL IN HEART FAILURE Cilostazol is STRICTLY CONTRAINDICATED in patients with Heart Failure of ANY severity (NYHA Class I, II, III, or IV; reduced or preserved ejection fraction).

Phosphodiesterase-3 inhibitors (such as milrinone and cilostazol) increase intracellular cAMP in cardiomyocytes, which in the failing heart triggers fatal ventricular tachyarrhythmias and significantly increases all-cause mortality. Before prescribing cilostazol, clinicians must review the medical record and confirm the absence of heart failure.

• Pentoxifylline: A xanthine derivative marketed to decrease blood viscosity and improve erythrocyte deformability. Large randomized clinical trials demonstrate marginal efficacy comparable to placebo. Modern ACC/AHA guidelines designate pentoxifylline as not effective and do not recommend its use.

---

Indications for Surgical & Endovascular Revascularization

Revascularization of the lower extremity is not indicated for asymptomatic disease or mild, stable claudication. Revascularization is reserved for three distinct clinical scenarios:

1. Chronic Limb-Threatening Ischemia (CLTI): Patients presenting with ischemic rest pain, non-healing ischemic ulcers, or tissue gangrene require urgent anatomic imaging (CT angiography, MR angiography, or catheter digital subtraction angiography) and prompt revascularization to avert limb loss.
2. Acute Limb Ischemia (ALI): Sudden loss of limb perfusion characterized by the 6 Ps: Pain, Pallor, Pulselessness, Poikilothermia (cold limb), Paresthesias, and Paralysis. ALI is a surgical emergency requiring immediate systemic anticoagulation (IV heparin bolus and infusion) and emergent vascular surgery consultation for catheter-directed thrombolysis, surgical embolectomy, or bypass within 4 to 6 hours to prevent irreversible neuromuscular necrosis.
3. Severe, Disabling Claudication Refractory to Conservative Therapy: When claudication significantly impairs the patient's functional capacity, occupational ability, or lifestyle, and has failed to improve despite a minimum of 3 to 6 months of supervised exercise therapy and optimal guideline-directed medical therapy.

Endovascular vs. Surgical Modalities

• Endovascular Therapy: Percutaneous transluminal angioplasty (PTA), drug-coated balloons (paclitaxel-eluting), and bare-metal or covered stenting. First-line approach for focal, short-segment stenoses/occlusions (e.g., iliac stenosis, localized superficial femoral artery lesions), offering lower perioperative morbidity.
• Surgical Bypass: Indicated for extensive, diffuse, multi-segment occlusions or when endovascular approaches fail. Prototypic procedure: femoropopliteal bypass grafting. The autologous greater saphenous vein is the conduit of choice, offering 5-year patency rates exceeding 75% to 80%, vastly superior to synthetic polytetrafluoroethylene (PTFE) grafts.